- Date de dépôt
- 18 July 2006
- Mots clés
- Pays de la méchanceté
- État actuel
-
Rejected
- Secteur
- NCP
Allégations
Ratiopharm, a pharmaceuticals company and major producer of generic drugs, has allegedly engaged in unethical marketing practices, including bribing doctors and pharmacists in Belgium, Canada, Spain, Estonia and Germany.
Les directives pertinentes de l’OCDE
Résultat
In December 2006, the German NCP rejected the second complaint against Ratiopharm. The NCP argued that the complaint would had to be dealt with by the NCP of the country where the alleged misbehaviour occurred, i.e. Belgium, Canada, Estonia, and Spain.
Transparency International and the NCP met informally in March 2007. Again, the NCP insisted it could not accept the Ratiopharm case and refused to forward it to the relevant NCPs. The NCP claimed its “hands were tied”.
Transparency International maintains that the alleged misbehaviour emanates from Ratiopharm’s German headquarters to other countries. Therefore, the German NCP should take the lead in handling the complaint. In addition, the NCP’s refusal to forward the case to the other relevant NCPs inspires little faith in the NCP’s offer to assist informally.
Plus de détails
- Plaignant
- Entreprise en infraction
- Les plaignants
- Personnes touchées
- Date rejetée / conclue
- 1 December 2007
Complaints connexes
- Gresea & Transparency International Germany vs Ratiopharm
- Transparency International Germany vs. Ratiopharm